PMID: 8602114Jan 1, 1996Paper

(-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons

Life Sciences
J KnollK Kelemen

Abstract

The activity of the catecholaminergic neurons in the rat brain is enhanced significantly 30 min after the subcutaneous injection of very small doses of (-)deprenyl (threshold doses: 0.01 mg/kg for noradrenergic neurons and 0.025 mg/kg for dopaminergic neurons). As a catecholaminergic activity enhancer (CAE) substance (-)deprenyl is about ten times more potent than its parent compound, (-)methamphetamine. While the (+)methamphetamine is 3-5 times more potent than (-)methamphetammine in releasing catecholamines, the (-)methamphetamine is the more potent CAE substance. The mechanism of the CAE effect of (-)deprenyl and (-)PPAP, a deprenyl-derived substance devoid of MAO inhibitory potency, was studied in rats by measuring: a) the release of catecholamines from striatum, substantia nigra, tuberculum olfactorium and locus coeruleus; b) the stimulation induced release of 3H-noradrenaline from the isolated brain stem; and c) the antagonistic effect against tetrabenazine-induced depression of learning in the shuttle box. The CAE effect was found to be unrelated: a) to the inhibition of MAO activity; b) to the inhibition of presynaptic catecholamine receptors; c) to the inhibition of the uptake of catecholamines; and d) to the release o...Continue Reading

References

Feb 1, 1977·Naunyn-Schmiedeberg's Archives of Pharmacology·T EndoH D Taube
Nov 16, 1989·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Jan 1, 1968·Pflügers Archiv für die gesamte Physiologie des Menschen und der Tiere·O RougierR Stämpfli
Jan 1, 1966·Psychopharmacologia·D BovetA Oliverio
Jan 1, 1995·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·J Knoll
Aug 1, 1994·Pharmacology & Toxicology·J Knoll
Jan 21, 1993·The New England Journal of Medicine·UNKNOWN Parkinson Study Group

❮ Previous
Next ❯

Citations

Jan 1, 1996·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·J Knoll
Apr 20, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Seiichiro Shimazu, Ildikó Miklya
Jan 1, 1997·Life Sciences·W W RuehlF F Hahn
Jun 19, 1998·Pharmacology, Biochemistry, and Behavior·M FerigoloM Tannhauser
Oct 20, 2001·Progress in Neuro-psychopharmacology & Biological Psychiatry·D Mills, R Ledger
Jun 19, 2001·Brain Research Bulletin·P S MohanKumarS K Quadri
Jul 1, 1997·Experimental Gerontology·J Knoll
Jul 2, 2008·Parkinsonism & Related Disorders·P FoleyP Riederer
Jul 6, 2004·The Journal of Pharmacy and Pharmacology·Maki YoshimuraKoji Sumikawa
Jul 19, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Peter Gaszner, Ildikó Miklya
Sep 6, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Seiichiro ShimazuFumio Yoneda
Oct 23, 2001·Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie·T SatouS Hashimoto
Dec 6, 2000·Journal of Psychopharmacology·D McGuire, K Marder

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.